Sweden's SciBase H1 revenue rises
Sweden's SciBase H1 revenue rises
Overview
Sweden medical technology firm's H1 net sales rose 68% yr/yr
Company posted higher net loss H1
Gross margin for H1 dropped to 51%, affected by currency and production costs
Outlook
Company did not provide specific financial guidance or outlook for the current or future periods in press release
Result Drivers
ELECTRODE SALES - Co said electrode sales volume increased 118% in Q2, with repeat sales to existing customers up 75%
MARKET EXPANSION - Sales in Germany skin cancer segment rose 18% and US skin cancer market sales rose 80% in Q2
GROSS MARGIN PRESSURE - Gross margin was negatively affected by currency development, higher gold prices, clinical study deliveries and production ramp-up
Company press release: ID:nWkr3P8kPC
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Sales |
| SEK 29.59 mln |
|
H1 Loss Per Share |
| SEK 5.80 |
|
H1 Net Loss |
| SEK 53.38 mln |
|
H1 Gross Margin |
| 51.00% |
|
Analyst Coverage
Wall Street's median 12-month price target for SciBase Holding AB (publ) is SEK50.00, about 89.4% above its August 18 closing price of SEK26.40
Reuters Recommended Reads
Aug 18 - Sweden's OssDsign Q2 sales rise 2.4% gross margin falls
Aug 19 - Sweden's Cantargia narrows H1 loss, raises SEK 132 mln
Aug 18 - Denmark's Coloplast Q3 revenue up on Chronic Care, Urology growth
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)